Literature DB >> 2984107

DNA polymorphisms flanking the apo A-1 and insulin genes and type III hyperlipidaemia.

M Vella, A Kessling, N Jowett, A Rees, J Stocks, S Wallis, D Galton.   

Abstract

Two alleles identified by DNA restriction fragment length polymorphisms around the apo A-1/C-III and insulin genes have been shown to be associated with Type IV and V hyperlipidaemia. We have genotyped 19 patients with Type III hyperlipidaemia to establish whether this association is also found in the disorder. Our data show that these associations are not responsible for the majority of cases of Type III hyperlipidaemia, but cannot exclude the possibility that a small proportion (less than 50%) of cases of Type III are caused by interaction between these alleles and the apolipoprotein E2 phenotype.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984107     DOI: 10.1007/bf00293040

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  10 in total

1.  The log likelihood ratio test (the G-test); methods and tables for tests of heterogeneity in contingency tables.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1957-06       Impact factor: 1.670

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man.

Authors:  G Utermann; M Hees; A Steinmetz
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

4.  Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants.

Authors:  L M Kunkel; K D Smith; S H Boyer; D S Borgaonkar; S S Wachtel; O J Miller; W R Breg; H W Jones; J M Rary
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

5.  DNA polymorphism adjacent to human apoprotein A-1 gene: relation to hypertriglyceridaemia.

Authors:  A Rees; C C Shoulders; J Stocks; D J Galton; F E Baralle
Journal:  Lancet       Date:  1983-02-26       Impact factor: 79.321

6.  Association of isoapolipoprotein-E3 deficiency with heterozygous familial hypercholesterolaemia: implications for lipoprotein physiology.

Authors:  W R Hazzard; N Miller; J J Albers; G R Warnick; P Baron; B Lewis
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

7.  Insulin and apolipoprotein A-1/C-III gene polymorphisms relating to hypertriglyceridaemia and diabetes mellitus.

Authors:  N I Jowett; A Rees; L G Williams; J Stocks; M A Vella; G A Hitman; J Katz; D J Galton
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

8.  Diabetic hypertriglyceridaemia and related 5' flanking polymorphism of the human insulin gene.

Authors:  N I Jowett; L G Williams; G A Hitman; D J Galton
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

9.  Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.

Authors:  J L Breslow; V I Zannis; T R SanGiacomo; J L Third; T Tracy; C J Glueck
Journal:  J Lipid Res       Date:  1982-11       Impact factor: 5.922

10.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.

Authors:  W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  10 in total
  10 in total

1.  Haplotypes identified by DNA polymorphisms at the apolipoprotein A-1 and C-III loci and hypertriglyceridaemia. A study in a Japanese population.

Authors:  A Rees; J Stocks; H Paul; Y Ohuchi; D Galton
Journal:  Hum Genet       Date:  1986-02       Impact factor: 4.132

Review 2.  DNA polymorphism and the study of disease associations.

Authors:  D N Cooper; J F Clayton
Journal:  Hum Genet       Date:  1988-04       Impact factor: 4.132

Review 3.  Diagnosis of genetic disease using recombinant DNA.

Authors:  D N Cooper; J Schmidtke
Journal:  Hum Genet       Date:  1986-05       Impact factor: 4.132

4.  Haplotypes of the human apoprotein AI-CIII-AIV gene cluster in coronary atherosclerosis.

Authors:  G A Ferns; D J Galton
Journal:  Hum Genet       Date:  1986-07       Impact factor: 4.132

5.  Linkage disequilibrium of three polymorphic RFLP markers in the apolipoprotein AI-CIII gene cluster on chromosome 11.

Authors:  O Marasco; F Melina; E Mele; B Quaresima; A Zingone; E Focarelli; E Picciotti; M L Martelli; L Fotino; M F Vigna
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

6.  DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias.

Authors:  M R Hayden; H Kirk; C Clark; J Frohlich; S Rabkin; R McLeod; J Hewitt
Journal:  Am J Hum Genet       Date:  1987-05       Impact factor: 11.025

7.  A DNA polymorphism of an apoprotein gene associates with the hypertriglyceridaemia of primary gout.

Authors:  G A Ferns; J Lanham; P Dieppe; D J Galton
Journal:  Hum Genet       Date:  1988-01       Impact factor: 4.132

8.  Extracoronary atherosclerosis and genetic variants of apolipoprotein AI-CIII cluster in myocardial infarction survivors from southern Italy.

Authors:  F De Lorenzo; A Monticelli; S Cocozza; B De Simone; P Rubba
Journal:  Clin Investig       Date:  1994-06

9.  Association of a DNA polymorphism in the apolipoprotein C-III gene with diverse hyperlipidaemic phenotypes.

Authors:  H E Henderson; S V Landon; J Michie; G M Berger
Journal:  Hum Genet       Date:  1987-01       Impact factor: 4.132

10.  DNA markers in the hyperlipidaemias and atherosclerosis.

Authors:  A Rees
Journal:  J R Coll Physicians Lond       Date:  1987-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.